Esophago-tracheobronchial fistula induced by anlotinib: A case report

The incidence of adverse reactions to anlotinib is relatively low, and esophago-tracheobronchial fistula caused by it is even rarer. When using anlotinib to treat non-small cell lung cancer, clinicians need to monitor changes in patients' symptoms closely. If symptoms of choking when eating and drinking occur, pulmonary computed tomography should be promptly repeated to detect signs of esophago-tracheobronchial fistula early and intervene promptly.